Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

OBJECTIVE: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Autores principales: Wade, K.N. Slaughter, Brady, M.F., Thai, T., Wang, Y., Zheng, B., Salani, R., Tewari, K.S., Gray, H.J., Bakkum-Gamez, J.N., Burger, R.A., Moore, K.N., Bookman, M.A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048388/
https://ncbi.nlm.nih.gov/pubmed/31409486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.07.020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares